Matches in Wikidata for { <http://www.wikidata.org/entity/Q94143162> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q94143162 description "article scientifique publié en 2019" @default.
- Q94143162 description "im Oktober 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q94143162 description "wetenschappelijk artikel" @default.
- Q94143162 description "наукова стаття, опублікована в жовтні 2019" @default.
- Q94143162 name "663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Pha" @default.
- Q94143162 name "663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Pha" @default.
- Q94143162 type Item @default.
- Q94143162 label "663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Pha" @default.
- Q94143162 label "663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Pha" @default.
- Q94143162 prefLabel "663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Pha" @default.
- Q94143162 prefLabel "663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Pha" @default.
- Q94143162 P1433 Q94143162-0ABF594F-B6D9-4B29-B649-0268EACA14BF @default.
- Q94143162 P1476 Q94143162-18D8DAA7-C0A2-47BE-9E6E-0BFC0880B0AB @default.
- Q94143162 P2093 Q94143162-1A50B47A-B44F-4612-BCE8-05D7CA5773C9 @default.
- Q94143162 P2093 Q94143162-28B03FEA-5AA6-447B-B223-C18E34FB6756 @default.
- Q94143162 P2093 Q94143162-44F54716-9AAA-48BC-AE4F-864B1BA57E3A @default.
- Q94143162 P2093 Q94143162-548B416F-4FE1-4CBD-8C44-2887EDC346AF @default.
- Q94143162 P2093 Q94143162-8786C722-65DB-4AC8-AB9E-ED261DA48FF2 @default.
- Q94143162 P2093 Q94143162-AAA4598E-4161-4173-AF5A-A8737C45A981 @default.
- Q94143162 P2093 Q94143162-C345E78F-5531-447A-A289-BD1264AD1016 @default.
- Q94143162 P2093 Q94143162-CC0DA415-DC06-46AD-91EC-6849B58A55F6 @default.
- Q94143162 P2093 Q94143162-D4DF34D0-F2E1-4945-8094-04E4D383E075 @default.
- Q94143162 P275 Q94143162-da6edbee-6968-40d8-a6f7-095c85131005 @default.
- Q94143162 P304 Q94143162-C20E4D94-BFC2-4B80-9EE2-77AD3DAEAA68 @default.
- Q94143162 P31 Q94143162-57E95B3D-CF03-48EB-A797-E50C084C9477 @default.
- Q94143162 P356 Q94143162-AD4CB437-C4AF-40FC-915E-1EC3BFC09DE5 @default.
- Q94143162 P433 Q94143162-A9E87497-C824-44EB-838F-B3814F78ACFF @default.
- Q94143162 P478 Q94143162-EF85B28D-427D-4C2C-A959-B4BD95A1B06E @default.
- Q94143162 P50 Q94143162-6E538305-2F5B-49F5-B1D7-759DAE5AECF7 @default.
- Q94143162 P577 Q94143162-313847E0-21AD-4083-880F-46339125EC3D @default.
- Q94143162 P6216 Q94143162-3d84ed36-c48e-4f63-bf8c-d45c7639ff46 @default.
- Q94143162 P921 Q94143162-116E888E-D923-42BF-8518-5CF35DCFAFE3 @default.
- Q94143162 P921 Q94143162-AA3266DA-917D-42B8-AD7E-2C3EE4CB46FD @default.
- Q94143162 P921 Q94143162-E5878C8F-C448-42CC-B060-76F241657355 @default.
- Q94143162 P932 Q94143162-56CE8A79-801B-4D14-B48A-BCDD36141EA5 @default.
- Q94143162 P356 OFZ360.731 @default.
- Q94143162 P1433 Q27725953 @default.
- Q94143162 P1476 "663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials" @default.
- Q94143162 P2093 "Andrew F Shorr" @default.
- Q94143162 P2093 "Anita F Das" @default.
- Q94143162 P2093 "Christian Sandrock" @default.
- Q94143162 P2093 "Elizabeth Alexander" @default.
- Q94143162 P2093 "Gregory J Moran" @default.
- Q94143162 P2093 "Jennifer Schranz" @default.
- Q94143162 P2093 "Lisa Goldberg" @default.
- Q94143162 P2093 "Steven P Gelone" @default.
- Q94143162 P2093 "Susanne Paukner" @default.
- Q94143162 P275 Q24082749 @default.
- Q94143162 P304 "S303-S304" @default.
- Q94143162 P31 Q13442814 @default.
- Q94143162 P356 "10.1093/OFID/OFZ360.731" @default.
- Q94143162 P433 "Suppl 2" @default.
- Q94143162 P478 "6" @default.
- Q94143162 P50 Q124419900 @default.
- Q94143162 P577 "2019-10-23T00:00:00Z" @default.
- Q94143162 P6216 Q50423863 @default.
- Q94143162 P921 Q147885 @default.
- Q94143162 P921 Q3776920 @default.
- Q94143162 P921 Q424940 @default.
- Q94143162 P932 "6810975" @default.